Chong CCN, Wong GLH, Lai PBS. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 6006-6012 [PMID: 24876723 DOI: 10.3748/wjg.v20.i20.6006]
Corresponding Author of This Article
Charing Ching Ning Chong, MBChB, MSc, FCSHK, Division of Hepato-biliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, the Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong, China. chongcn@surgery.cuhk.edu.hk
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 28, 2014; 20(20): 6006-6012 Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6006
Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma
Charing Ching Ning Chong, Grace Lai Hung Wong, Paul Bo San Lai
Charing Ching Ning Chong, Paul Bo San Lai, Division of Hepato-biliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong, China
Grace Lai Hung Wong, Institute of Digestive Disease and Department of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong, China
Author contributions: Chong CCN, Wong GLH and Lai PBS contributed equally to this work; Chong CCN contributed to the acquisition, analysis and interpretation of data, and drafting the article; Wong GLH contributed to the drafting and revising the article; Lai PBS contributed to the conception and design, and revising it critically for important intellectual content.
Correspondence to: Charing Ching Ning Chong, MBChB, MSc, FCSHK, Division of Hepato-biliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, the Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong, China. chongcn@surgery.cuhk.edu.hk
Telephone: +852-2-6321496 Fax: +852-2-6377974
Received: November 7, 2013 Revised: February 2, 2014 Accepted: March 18, 2014 Published online: May 28, 2014 Processing time: 201 Days and 19.6 Hours
Core Tip
Core tip: The impact of antiviral therapy on clinical outcomes after curative liver resection in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains to be established. There are increasing evidence to suggest that antiviral therapy could suppress HBV replication, decrease the perioperative reactivation of virus, reduce liver injury, preserve the liver function before and after operation, and may lower the risk of HCC recurrence. Antiviral therapy may also improve the survival after liver resection by reducing recurrence and delaying the liver damage by the virus, rendering in a higher chance of receiving aggressive salvage therapy during HCC recurrence. We herein review the currently available evidences on this issue.
